Rentokil Initial (LON:RTO) First Half 2025 Results

Key Financial Results

Revenue: UK£3.36b (up 3.0% from 1H 2024). Net income: UK£164.0m (down 28% from 1H 2024). Profit margin: 4.9% (down from 7.0% in 1H 2024). EPS: UK£0.065 (down from UK£0.091 in 1H 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.LSE:RTO Earnings and Revenue Growth August 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Rentokil Initial EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Commercial Services industry in the United Kingdom.

Performance of the British Commercial Services industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted  4 warning signs for Rentokil Initial you should be aware of, and 1 of them is potentially serious.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments